Targeted molecular therapies for ovarian cancer: an update and future             perspectives (Review).
Identification of the potential gene expression profiles of epithelial ovarian             cancer and the arrival of newly targeted therapies have advanced the strategies             used for treatment of this disease. This review focuses on the design of ongoing             and planned clinical trials and offers a synopsis of the English-language literature             for preclinical and clinical targeted therapies for epithelial ovarian cancer.             Among many targeted agents, a promising, novel class of targeted drugs for special             patient populations expected to improve the effectiveness of current therapy include             inhibitors of angiogenesis, poly (ADP ribose) polymerase (PARP) and DNA repair             mechanisms. Inhibition of PARP or homologous recombination (HR) repair mediated             by Chk1 (checkpoint kinase 1) would selectively sensitize p53 mutation, BRCAness             phenotype (serous type ovarian cancer) or HNF (hepatocyte nuclear factor)-1β-overexpressing             tumor cells (clear cell type ovarian cancer) to chemotherapeutic agents. The therapeutic             response is likely to be limited to a targeted patient, but not to the broad population.             This review discusses some of the key current developments and existing challenges.
Department of Obstetrics and Gynecology, Nara Medical University,                     Nara 634-8522, Japan.
Hiroshi
H
Shigetomi
Yumi
Y
Higashiura
Hirotaka
H
Kajihara
Hiroshi
H
Kobayashi
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology
D000970:Antineoplastic Agents